Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain

Brain Research

Volumn 1155, Issue 1, 2007, Pages 208-219

  Higashi, Shinji ^a,b   Biskup, Saskia ^c   West, Andrew B ^c   Trinkaus, Daniel ^c   Dawson, Valina L ^c   Faull, Richard L M ^d   Waldvogel, Henry J ^d   Arai, Heii ^b   Dawson, Ted M ^c   Moore, Darren J ^c   Emson, Piers C ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Dardarin; Dementia with Lewy bodies (DLB); Lewy body (LB); PARK8; Parkinson's disease (PD); Parkinsonism

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; ALPHA SYNUCLEIN; CALRETININ; DOPAMINE; FLUORESCENT DYE; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA;

ADULT; AGED; ALPHA SYNUCLEOPATHY; ARTICLE; AUTOPSY; AUTOSOMAL DOMINANT DISORDER; BRAIN CORTEX; BRAIN REGION; BRAIN TISSUE; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; DEMENTIA; DOPAMINERGIC NERVE CELL; FAMILIAL DISEASE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; INNERVATION; LEWY BODY; LRKK2 GENE; MALE; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PUTAMEN; SUBSTANTIA NIGRA;

BRAIN; CAUDATE NUCLEUS; CEREBRAL CORTEX; CORPUS STRIATUM; HUMANS; IN SITU HYBRIDIZATION; LEWY BODIES; MUTATION; NEURONS; PARKINSONIAN DISORDERS; PROTEIN-SERINE-THREONINE KINASES; PUTAMEN; REFERENCE VALUES;

EID: 34250199013     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.04.034     Document Type: Article

References (35)

1. Bettler B., Kaupmann K., Mosbacher J., and Gassmann M. Molecular structure and physiological functions of GABA(B) receptors. Physiol. Rev. 84 (2004) 835-867
2. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., Faull R.L., Emson P.C., Torp R., Ottersen O.P., Dawson T.M., and Dawson V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60 (2006) 567-569
3. Covy J.P., Van Deerlin V.M., and Giasson B.I. Lack of evidence for Lrrk2 in α-synuclein pathological inclusions. Ann. Neurol. 60 (2006) 618-619
4. Di Fonzo A., Rohe C.F., Ferreira J., Chien H.F., Vacca L., Stocchi F., Guedes L., Fabrizio E., Manfredi M., Vanacore N., Goldwurm S., Breedveld G., Sampaio C., Meco G., Barbosa E., Oostra B.A., and Bonifati V. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365 (2005) 412-415
5. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., and Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51 (2002) 296-301
6. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., Tsuji S., and Obata F. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 57 (2005) 918-921
7. Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O., and Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 59 (2006) 714-719
8. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., and Van Deerlin V.M. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59 (2006) 315-322
9. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J., Healy D.G., Holton J.L., Revesz T., and Wood N.W. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (2005) 415-416
10. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., Kolch W., Prokisch H., and Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15 (2006) 223-232
11. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., and Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23 (2006) 329-341
12. Haugarvoll K., and Wszolek Z.K. PARK8 LRRK2 Parkinsonism. Curr. Neurol. Neurosci. Rep. 6 (2006) 287-294
13. Herbison A.E., Simonian S.X., Norris P.J., and Emson P.C. Relationship of neuronal nitric oxide synthase immunoreactivity to GnRH neurons in the ovariectomized and intact female rat. J. Neuroendocrinol. 8 (1996) 73-82
14. Higashi S., Moore D.J., Colebrooke R.E., Biskup S., Dawson V.L., Arai H., Dawson T.M., and Emson P.C. Expression and localization of Parkinson's disease-associated Leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 100 (2007) 368-381
15. Kachergus J., Mata I.F., Hulihan M., Taylor J.P., Lincoln S., Aasly J., Gibson J.M., Ross O.A., Lynch T., Wiley J., Payami H., Nutt J., Maraganore D.M., Czyzewski K., Styczynska M., Wszolek Z.K., Farrer M.J., and Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76 (2005) 672-680
16. Kaneko T., Cho R., Li Y., Nomura S., and Mizuno N. Predominant information transfer from layer III pyramidal neurons to corticospinal neurons. J. Comp. Neurol. 423 (2000) 52-65
17. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., and Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29 (2006) 286-293
18. Melrose H., Lincoln S., Tyndall G., Dickson D., and Farrer M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139 (2006) 791-794
19. Miklossy J., Arai T., Guo J.P., Klegeris A., Yu S., McGeer E.G., and McGeer P.L. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 65 (2006) 953-963
20. Moore D., Chambers J., Waldvogel H., Faull R., and Emson P. Regional and cellular distribution of the P2Y(1) purinergic receptor in the human brain: striking neuronal localisation. J. Comp. Neurol. 421 (2000) 374-384
21. Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S., Halter C.A., Michaels V.E., Reed T., Rudolph A., Shults C.W., Singleton A., and Foroud T. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365 (2005) 410-412
22. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
23. Rajput A., Dickson D.W., Robinson C.A., Ross O.A., Dachsel J.C., Lincoln S.J., Cobb S.A., Rajput M.L., and Farrer M.J. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67 (2006) 1506-1508
24. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., Litvan I., Gordon M.F., Wszolek Z.K., Farrer M.J., and Dickson D.W. Lrrk2 and Lewy body disease. Ann. Neurol. 59 (2006) 388-393
25. Simon-Sanchez J., Herranz-Perez V., Olucha-Bordonau F., and Perez-Tur J. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci. 23 (2006) 659-666
26. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., and Ross C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18676-18681
27. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., and Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9 (2006) 1231-1233
28. Taymans J.M., Van den Haute C., and Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 98 (2006) 561-571
29. Waldvogel H.J., Billinton A., White J.H., Emson P.C., and Faull R.L. Comparative cellular distribution of GABAA and GABAB receptors in the human basal ganglia: immunohistochemical colocalization of the alpha 1 subunit of the GABAA receptor, and the GABABR1 and GABABR2 receptor subunits. J. Comp. Neurol. 470 (2004) 339-356
30. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16842-16847
31. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16 (2007) 223-232
32. Wszolek Z.K., Pfeiffer R.F., Tsuboi Y., Uitti R.J., McComb R.D., Stoessl A.J., Strongosky A.J., Zimprich A., Muller-Myhsok B., Farrer M.J., Gasser T., Calne D.B., and Dickson D.W. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62 (2004) 1619-1622
33. Zhu X., Siedlak S.L., Smith M.A., Perry G., and Chen S.G. LRRK2 protein is a component of Lewy bodies. Ann. Neurol. 60 (2006) 517-518
34. Zhu X., Babar A., Siedlak S.L., Yang Q., Ito G., Iwatsubo T., Smith M.A., Perry G., and Chen S.G. LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol. Neurodegener. 1 (2006) 17
35. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607